Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF) - 17/12/18
![](/templates/common/images/mail.png)
on behalf of the SODIUM-HF investigators
Abstract |
Background |
Patients with heart failure (HF) remain at high risk for future events despite medical and device therapy. Dietary sodium reduction is often recommended based on limited evidence. However, it is not known whether dietary sodium reduction reduces the morbidity or mortality associated with HF.
Methods |
The SODIUM study is a pragmatic, randomized, open-label trial assessing the efficacy of dietary sodium reduction to <1500 mg daily counseling compared to usual care for patients with chronic HF. The intervention is provided by trained personnel at the site and uses 3-day food records for directing counseling. The primary outcome is an intention-to-treat analysis on the time to first cardiovascular event or death measured at 12 months. Secondary end points include the change in quality of life (using the Kansas City Cardiomyopathy Questionnaire), change in New York Heart Association class, and change in 6-minute walk test. The first patient was enrolled in March 2014, and subsequently, 27 sites in 6 countries enrolled patients.
Conclusions |
The SODIUM-HF trial will provide a robust evaluation of the effects of dietary sodium reduction in patients with HF. Results are expected in 2020.
Le texte complet de cet article est disponible en PDF.Plan
Philip F. Binkley, MD, MPH, served as guest editor for this article. |
|
RCT# NCT02012179 |
|
Funding: SODIUM-HF (www.sodiumhftrial.com) is funded by the Canadian Institutes of Health Research (CIHR MOP 130275) and the University Hospital Foundation (Edmonton, Alberta, Canada). |
|
Disclosures: none. |
Vol 205
P. 87-96 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?